MedTrace Logo

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

NCT05585580 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2025-01-07

No results posted yet for this study

Summary

This is a prospective, single arm, multicenter phase II study to assess the effectiveness of Serplulimab, Lenvatinib and Paclitaxel in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma after first-line immunotherapy.

Conditions

  • Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

Serplulimab

300mg d1 q3w

DRUG

Lenvatinib

8mg po qd

DRUG

Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome

135\~175mg/m2 /260mg/m2/135-175mg/m2 d1 q3w

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    lead OTHER

Principal Investigators

  • Lian Liu · Qilu hospital of Shandong univertisy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2025-11-01
Completion
2026-11-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05585580 on ClinicalTrials.gov